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Table 1
Patients' current therapy at enrollment
CD (N=414) UC (N=245)
5ASA 88 21% 177 72%
ATB 20 5% 9 4%
AZA/6MP 208 50% 98 40%
Anti-TNF 98 24% 20 8%
MTX 48 12% 8 3%
CST 112 27% 87 36%
Other 75 18% 45 18%
prospective data in order to evaluate disease course using these therapies,
as well as their appropriateness (http://www.epact.ch).
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STUDY OF THIOPURINE-METHYL-TRANSFERASE (TPMT) GENOTYPE AND
PHENOTYPE IN AN ITALIAN POPULATION
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1ASO Ordine Mauriziano, Torino, Italy; 2Pharmacology Unit, Turin
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Background: Immunomodulating regimens, mainly based on thiopurines, are
increasingly prescribed in inflammatory bowel disease (IBD). Thiopurine-
methyl-transferase (TPMT) genotype and phenotype is expected to exhert
notable effects on availability and toxicity of these drugs, but it may vary
considerably in different populations.
Aim of the study: Aim of this study was to analyse TPMT genotype and phe-
notype in a Northern Italian population of healthy controls and IBD patients.
Patients and methods: The study protocol was accepted by local Ethical
Committee. All consecutive IBD out-patients (n=169) and 533 healthy con-
trols (HC) were recruited. A blood sample was drawn, DNA was extracted
for genetic analyses and erytrocytes were separated. Major TPMT genetic
variants (TPMT*2, *3A, *3B, *3C) were analysed by means of standardised
PCR techniques, while intra-erythrocyte TMPT activity was analysed using a
standardised high pressure liquid chromatography (HPLC) technique. Clinical
data were recorded for IBD patients.
Results: Regarding TPMT genotype, TPMT was mutated in 8/169 (4.7%; 95%CI
1.5-8%) IBD cases (7 heterozigous for *3A and 1 for *3C, respectively) and in
34/533 (6.4%; 95%CI 4-8%) HC (28 heterozigous for *3A, 3 for *3B and 3 for
*3C, respectively); the difference was not statistically significant (p=0.549).
Hardy Weinberg distribution was respected, no mutant homozygous was ob-
served among the cases or controls. No significant differences were noted
for any subgroup analysis.
As for TPMT activity, the distribution of TPMT activity was sharply different
in IBD cases, with distribution not-normal (p<0.001) and significantly lower
than among HC (however not-normally distributed, p=0.014). TPMT activity
figures are reported in Table 1.
Table 1
TPMT P
nMol/h/g Hgb IQR
HC (n=533) 33.23 26.61-42.04 comparator
IBD cases (n=169) 27.16 21.45-46.85 0.0016
Crohn' s disease (n=79) 27.82 20.80-45.11 0.0175
Ulcerative/indeterminate colitis (n=90) 27.02 21.65-29.89 0.0168
No significant TPMT phenotype difference was noted based on IBD subgroups
based on TPMT genotype or on other clinical characteristic, but we found
that IBD patients on systemic steroids (n=16) had higher median TPMT activ-
ity (46.54 nMol/h/g Hgb) compared to those not on steroid treatment (n=153,
26.98 nMol/h/g Hgb), p=0.0023.
Discussion: This is the first report on TPMT genotypic and phenotypic char-
acteristics of a Northern Italian population. No difference was observed for
TPMT genotype when comparing cases and controls, however allelic fre-
quency was lower than expected and no homozygous mutant subject was
observed (at very high risk of adverse event if on thiopurine treatment).
TPMT activity was lower in IBD patients compared to healthy controls.
Larger groups of patients are under investigation in order to confirm these
observations.
Financial disclosure: All Authors state they have no conflict of interest to
disclose.
The study was supported by Fondazione IBD Onlus and funded by Compagnia
di San Paolo (ref. 2002.117) and Regione Piemonte
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CARD15 GENE EXPRESSION AND ACTIVITY AND PHENOTYPE OF CROHN'S
DISEASE
E. Poniewierka, K. Neubauer, R. Kempinski, L. Paradowski,
A. Sadakierska-Chudy, T. Dobosz. Wroclaw Medical University, Wroclaw,
Poland
Aim: Familial aggregations of Crohn' s disease (CD) have suggested the influ-
ence of genetic factors in the disease development. CARD15 gene has been
the first susceptibility gene known for CD. Aim of our study was evaluation of
CARD15 gene expression in different subgroups of CD patients living in Lower
Silesia, Poland.
Material and method: CARD15 gene expression was assessed in 90 individu-
als: 60 patients with CD (30 females, 30 males) hospitalized in Department of
Gastroenterology and Hepatology, Wroclaw Medical University and in the con-
trol group (30 healthy volunteers). CARD15 gene expression was compared
to: phenotype of CD (according to the Montreal Classification for Crohn' s
disease (age of diagnosis, location, behavior)), presence of extraintestinal
symptoms and disease activity basing on lab tests and CDAI. CARD15 gene
expression was measured in peripheral mononuclear cells using real-time
RT-PCR. Total RNA was extracted using E.Z.N.A. Total RNA Kit (Omega Bio-
Tek). Total RNA was reverse transcribed by the TaqMan Reverse Transcrip-
tion Reagents (Roche). All quantitative real-time PCR (TaqManTM) primers,
probes and Universal master mix were obtained from Applied Biosystems
(USA). All PCRs were performed utilizing 5 µl cDNA per reaction in triplicates
of 25 µl volume on a ABI Prism 7900HT Sequence Detection System (TaqMan)
using a 2-step PCR protocol after the initial denaturing of the cDNA (10 min at
95°C) with 45 cycles of 95°C for 15 s and 60°C for 1 min. cDNA aliquots were
quantified for target genes using the threshold cycle (Ct) method normalized
for the house keeping gene GAPDH.
Results: CARD15 expression in peripheral mononuclear cells in CD patients
was significantly higher than in controls. The highest CARD15 expression
was found in CD patients in forth decade of life. Additionally, we observed
higher CARD15 expression in patients with disease duration between 12 and
60 months. There was no relation between CD phenotype and CARD15 ex-
pression. However, we found positive correlation of both, CDAI and classical
inflammatory markers values (ESR, CRP) and CARD15 expression.
Conclusion: Expression of gene CARD15 in Crohn' s disease is higher than in
healthy individuals. Disease activity, and not disease phenotype, seems to be
the most important factor influencing CARD15 expression.
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CLINICAL FEATURES AND PATHOGENESIS OF INFLAMMATORY BOWEL
DISEASE-ASSOCIATED INTESTINAL CANCER
Z. Szepes, I. Nemeth, T. Molnar, F. Nagy, L. Tiszlavicz, J. Lonovics,
T. Wittmann. Univ. Of Szeged, Szeged, Hungary
Patients with inflammatory bowel disease (IBD) [ulcerative colitis (UC) and
Crohn' s disease (CD)] are at an increased risk of developing gastrointesti-
nal, and mainly colorectal cancer (CRC). The main risk factors are the long-
standing duration of the disease, extensive colitis, chronic stenosis, primary
sclerosing cholangitis and a family history of CRC. The estimated prevalence,
the risk factors, the clinical features and the molecular pathogenetic alter-
ations of IBD-associated intestinal carcinoma were examined retrospectively
in a cohort of patients with IBD from a well-defined East-Hungarian geo-
graphical area.
Methods: 14 patients with IBD-associated intestinal cancer (10 with UC and 4
with CD; 13 with CRC and 1 with small bowel cancer) were evaluated at the
University of Szeged between 1987 and 2005. Medical records were reviewed
retrospectively for endoscopic and histologic characteristics and for detailed
clinical phenotypes. The following parameters were investigated by a tissue
microarray technique in the tumor and in auto control healthy tissues: the
grade of differentiation, the lymphovascular invasion, the perineural spread,
peritumoral inflammation, necrosis, the desmoplastic reaction and the gene
expression profiles of p53, MLH1, MSH2, β-catenin, PTEN, APC, K-ras, Cox-2,
NOS, NF?B and VEGF.
Results: The estimated prevalence of IBD-associated intestinal cancer among
all CD and UC patients during the examined period was 0.015%. The median
age at diagnosis of the IBD-related intestinal cancer cases was 56 years; the
median duration was 23.7 years. The main risk factors were chronic activ-
ity, extension of the disease and a positive familial anamnesis for CRC. 8/14
of the IBD-related tumors were distal to the splenic flexure. The inflamma-
tory markers were positive in all tumors. The molecular alterations found in
IBD-associated cancers involved the same targets as in sporadic CRC.
Conclusion: Chronic uncontrolled inflammation leads to neoplastic trans-
formation on the main molecular pathways of colon carcinogenesis in IBD
patients. Thus, the central question of carcinoma prevention in IBD is the
continuous control of inflammation throughout the gastrointestinal tract.
